Optomed Plc: Interim report January – March 2026

Optomed reported Q1 2026 revenue of EUR 3.4 million, down 16.7% year on year, with currency-adjusted revenue declining 15.4%. Devices revenue fell 30.2% to EUR 1.1 million and Software revenue decreased 8.4% to EUR 2.3 million, while EBITDA remained at EUR -0.7 million, unchanged from the prior year. The update points to continued pressure in the Devices segment despite relatively steadier Software performance.

Analysis

The key read-through is not just cyclical softness, but a worsening mix shift: the higher-margin device side is weakening faster than software, which implies operating leverage is moving against them even before any further top-line deterioration. If device revenue continues to lag, the company becomes increasingly dependent on software to stabilize gross margin, but software alone may not be able to offset fixed cost absorption in a small revenue base. That raises the risk that EBITDA stays pinned near current loss levels even if headline revenue flattens from here.

Second-order, a weaker device cycle can ripple through channel inventory, distributor ordering, and hospital purchasing cadence. In medtech, a 1-quarter revenue miss often creates 2-3 quarters of cautious ordering as buyers wait for pricing concessions or product refreshes, so the near-term risk is less about this quarter and more about a prolonged demand air pocket into summer and early autumn. Currency headwinds are manageable versus the core issue, but they reinforce that local-currency execution is also soft, not just FX-driven.

The contrarian angle is that the market may be extrapolating too linearly from a small base: with low absolute revenue, modest contract wins or a single replenishment cycle can swing growth rates sharply. If management can demonstrate device backlog stabilization or a step-up in software attach rate over the next 1-2 quarters, the bear case can unwind quickly because the stock likely embeds limited patience for sustained losses. Still, until evidence of sequential improvement appears, the path of least resistance is continued multiple compression versus better-capitalized medtech peers.

Key Decisions for Investors

• Maintain a tactical short bias on Optomed for the next 4-8 weeks into any post-earnings bounce; the setup favors fade rallies until sequential device stabilization is visible. Risk/reward improves if shares trade up on low volume without a clear guide-up.
• If borrow/liquidity allows, pair short Optomed vs long a higher-quality Nordic medtech/software name to isolate execution risk from sector beta; target 3-6 months, with the short leg benefiting from margin pressure and weak mix.
• Avoid buying the dip until there is at least one quarter of sequential improvement in Devices or a meaningful narrowing of EBITDA losses; the turnaround path likely needs 2-3 quarters before it is credible.
• For event-driven traders, consider a low-cost put spread expiring 2-4 months out to express downside from continued ordering softness while limiting theta bleed; the trade works best if management commentary confirms cautious customer behavior.